Stock Updates

How has AstraZeneca PLC:(NYSE:AZN) performed recently?

AstraZeneca PLC (NYSE: AZN) is a large market cap stock with a market cap of 84491.09. It is in the Drug Manufacturers – Major industry and sector Healthcare, with a current P/E of 37.93, a forward P/E of 14.73 and EPS of 0.88. At a stock price of 33.3 (0.76%) it has a dividend yield of 2.70%.

EPS growth for the last five years have been -16.70%, more recently this last year it has grown by 128.90%. The next year growth is going to be about -8.50% and more long-term -1.00% after five years. EPS growth quarter over quarter is -100.40%. Sales growth for the past five years have been -5.80% and sales growth quarter over quarter is -11.20%.

For performance, AstraZeneca PLC the past week has seen a gain of -1.62%. For the last month performance for AstraZeneca PLC is -1.16%. While the last quarter is 13.62% and half year, 16.28%. Finally for the year, performance is 10.00%.

The 52-week high for AstraZeneca PLC, is at -3.70%, and for the 52-week low it comes to a value of 25.12%. The 20-day simple moving average is 6.40% and 10.69% for the 200-day simple moving average.

Volatility for the week is at 1.76%, and for the month it is 1.31%. AstraZeneca PLC, has a target price of 35.5.

In terms of debt, long term debt/equity is 1.22, and for total debt/equity AstraZeneca PLC has 1.3. The gross margin is 82.20%, while operating margin is 15.00%, the profit margin is 9.20%. The current ratio is 0.9 and the quick ratio is 0.8.

Insider ownership is at 0.50%, with instituitional ownership at 12.20%. AstraZeneca PLC has a payout ratio of 108.10%. With the total shares outstanding coming to 2537.27. The shares float is 2503.33, with the float short at 1.21%, with short ratio coming to 4.95.

In terms of returns, the return on assets see AstraZeneca PLC, get 3.70%, with its returns on investment at 11.50%. Return on equity is 13.90%. So will the investors see the target price of 35.5, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Tony Dabbs

Leave a Comment